A BILL 
To direct the Secretary of Health and Human Services to 
award contracts, grants, and cooperative agreements to 
expand and enhance capacity for manufacturing covered 
products to prevent and control the spread of SARS– 
CoV–2 and COVID–19. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Coronavirus Vaccine 
4
and Therapeutic Development Act of 2021’’. 
5
23:02 Feb 07, 2021
H349
2 
•HR 349 IH
SEC. 2. COVERED PRODUCT DEVELOPMENT AND PROCURE-
1
MENT. 
2
(a) ENHANCING
DEVELOPMENT, PROCUREMENT, 
3
AND MANUFACTURING CAPACITY.— 
4
(1) IN GENERAL.—The Secretary of Health and 
5
Human Services shall, as appropriate, award con-
6
tracts, grants, and cooperative agreements, and 
7
enter into other transactions— 
8
(A) expanding and enhancing covered 
9
product research and development; 
10
(B) procuring covered products; and 
11
(C) expanding and enhancing capacity for 
12
manufacturing covered products. 
13
(2) AUTHORIZATION OF APPROPRIATIONS.—To 
14
carry out this subsection, there is authorized to be 
15
appropriated $20,000,000,000 for fiscal years 2021 
16
through 2025, to remain available until expended. 
17
(b) REPORT ON VACCINE AND THERAPEUTIC MANU-
18
FACTURING AND ADMINISTRATION CAPACITY.—Not later 
19
than December 31, 2021, the Secretary shall submit to 
20
the Committee on Energy and Commerce of the House 
21
of Representatives and the Committee on Health, Edu-
22
cation, Labor and Pensions of the Senate a report detail-
23
ing— 
24
(1) an assessment of the estimated supply of 
25
covered products necessary to prevent and control 
26
23:02 Feb 07, 2021
H349
3 
•HR 349 IH
the spread of SARS–CoV–2 and COVID–19, domes-
1
tically and internationally; 
2
(2) an assessment of current and future domes-
3
tic manufacturing capacity for covered products, in-
4
cluding identification of any gaps in manufacturing 
5
capacity, including— 
6
(A) identification of any gaps in capacity 
7
for manufacturing; and 
8
(B) an analysis of the effects of shifting 
9
manufacturing resources to address COVID–19; 
10
(3) activities conducted to expand and enhance 
11
manufacturing capacity for covered products to lev-
12
els sufficient to prevent and control the spread of 
13
SARS–CoV–2 and COVID–19, domestically and 
14
internationally, including a list and explanation of 
15
all contracts, grants, and cooperative agreements 
16
awarded, and other transactions entered into, for 
17
purposes of such expansion and enhancement and 
18
how such activities will help to meet future domestic 
19
manufacturing capacity needs; 
20
(4) a plan for the ongoing support of enhanced 
21
manufacturing capacity for covered products, domes-
22
tically and internationally; and 
23
(5) a plan— 
24
23:02 Feb 07, 2021
H349
4 
•HR 349 IH
(A) to ensure that manufacturing capacity 
1
meets the distribution targets and goals of cov-
2
ered products, domestically and internationally; 
3
and 
4
(B) to support the administration of cov-
5
ered products approved or authorized by the 
6
Food and Drug Administration to prevent and 
7
control the spread of SARS–CoV–2 and 
8
COVID–19, domestically and internationally, 
9
including Federal workforce enhancements nec-
10
essary to administer such products. 
11
(c) DEFINITIONS.—In this section: 
12
(1) The term ‘‘ancillary medical supply’’ in-
13
cludes— 
14
(A) vials; 
15
(B) bandages; 
16
(C) alcohol swabs; 
17
(D) syringes; 
18
(E) needles; 
19
(F) gloves and other personal protective 
20
equipment; and 
21
(G) other medical products the Secretary 
22
determines necessary for the administration of 
23
covered products. 
24
23:02 Feb 07, 2021
H349
5 
•HR 349 IH
(2) The term ‘‘covered product’’ means a vac-
1
cine, therapeutic, or ancillary medical supply to pre-
2
vent and control the spread of SARS–CoV–2 and 
3
COVID–19. 
4
(3) The term ‘‘Secretary’’ means the Secretary 
5
of Health and Human Services. 
6
Æ 
23:02 Feb 07, 2021
H349
